PRESS RELEASE published on 07/09/2024 at 20:45, 1 year 7 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
PRESS RELEASE published on 07/09/2024 at 20:45, 1 year 7 months ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers annuels pour 2023, avec une perte nette de 18,640 K€. La trésorerie s'élève à 3,9 M€. L'AG se tiendra le 13 septembre 2024 Résultats Financiers Assemblée Générale Trésorerie Perte Nette ACTICOR BIOTECH
BRIEF published on 05/15/2024 at 11:20, 1 year 9 months ago Résultats de l'étude ACTISAVE et perspectives futures d'ACTICOR BIOTECH ACTICOR BIOTECH Étude ACTISAVE Traitement AVC Glenzocimab ESOC 2024
BRIEF published on 05/15/2024 at 11:20, 1 year 9 months ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 1 year 9 months ago Informations privilégiées / Autres communiqués ACTICOR BIOTECH présente les résultats de l'étude ACTISAVE sur le traitement de l'AVC ischémique lors de l'ESOC 2024. Perspectives prometteuses pour le glenzocimab malgré l'absence d'efficacité globale ACTICOR BIOTECH Glenzocimab ESOC 2024 AVC Ischémique ACTISAVE
PRESS RELEASE published on 05/15/2024 at 11:15, 1 year 9 months ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 02/20/2026 at 18:30, 1 hour 42 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 4 hours 27 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 5 hours 42 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 6 hours 4 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 6 hours 12 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 1 hour 35 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 1 hour 40 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 2 hours 11 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 2 hours 11 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 18:00, 2 hours 12 minutes ago TERACT - Résiliation du contrat de liquidité
